Department of Anaesthesia and Intensive Care, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), M-607, km. 9, 100, 28034, Madrid, Spain.
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502. doi: 10.1007/s10096-020-04142-w. Epub 2021 Jan 3.
Bacterial and fungal co-infection has been reported in patients with COVID-19, but there is limited experience on these infections in critically ill patients. The objective of this study was to assess the characteristics and ouctome of ICU-acquired infections in COVID-19 patients. We conducted a retrospective single-centre, case-control study including 140 patients with severe COVID-19 admitted to the ICU between March and May 2020. We evaluated the epidemiological, clinical, and microbiological features, and outcome of ICU-acquired infections. Fifty-seven patients (40.7%) developed a bacterial or fungal nosocomial infection during ICU stay. Infection occurred after a median of 9 days (IQR 5-11) of admission and was significantly associated with the APACHE II score (p = 0.02). There were 91 episodes of infection: primary (31%) and catheter-related (25%) bloodstream infections were the most frequent, followed by pneumonia (23%), tracheobronchitis (10%), and urinary tract infection (8%) that were produced by a wide spectrum of Gram-positive (55%) and Gram-negative bacteria (30%) as well as fungi (15%). In 60% of cases, infection was associated with septic shock and a significant increase in SOFA score. Overall ICU mortality was 36% (51/140). Infection was significantly associated with death (OR 2.7, 95% CI 1.2-5.9, p = 0.015) and a longer ICU stay (p < 0.001). Bacterial and fungal nosocomial infection is a common complication of ICU admission in patients with COVID-19. It usually presents as a severe form of infection, and it is associated with a high mortality and longer course of ICU stay.
在 COVID-19 患者中已报道有细菌和真菌感染合并感染,但重症患者中这些感染的经验有限。本研究的目的是评估 COVID-19 患者 ICU 获得性感染的特征和结局。我们进行了一项回顾性单中心病例对照研究,纳入了 2020 年 3 月至 5 月期间入住 ICU 的 140 例重症 COVID-19 患者。我们评估了 ICU 获得性感染的流行病学、临床和微生物学特征及结局。57 例(40.7%)患者在 ICU 住院期间发生了细菌或真菌感染。感染发生于入组后中位 9 天(IQR 5-11),与急性生理与慢性健康状况评分系统 II 评分(APACHE II score)显著相关(p=0.02)。共发生 91 次感染:原发性(31%)和导管相关性(25%)血流感染最常见,其次是肺炎(23%)、气管支气管炎(10%)和尿路感染(8%),由广泛的革兰阳性菌(55%)、革兰阴性菌(30%)和真菌(15%)引起。60%的病例中感染与感染性休克和 SOFA 评分显著升高相关。总体 ICU 死亡率为 36%(51/140)。感染与死亡显著相关(OR 2.7,95%CI 1.2-5.9,p=0.015)和 ICU 住院时间延长(p<0.001)。COVID-19 患者 ICU 入住期间,细菌和真菌感染是常见并发症。它通常表现为严重感染形式,与高死亡率和 ICU 住院时间延长相关。